UROLOGIE CITADELLE: what changed
UROLOGIE CITADELLE
Largest movements
- Deferred charges and accrued income -€59,096
down €59,096 (-17.2%), from €343,133 to €284,037
- Cash +€38,363
up €38,363 (+28.6%), from €134,044 to €172,407
mainly Deferred charges and accrued income (+€59,096) and Net result for the year (+€8,348)
- Accrued charges and deferred income -€29,658
down €29,658 (-6.3%), from €467,620 to €437,962
- Profit (loss) carried forward +€8,348
up €8,348 (+72.5%), from -€11,509 to -€3,161
- Gross operating margin +€31,576
up €31,576, from -€22,256 to €9,320
- Financial charges +€362
up €362 (+198%), from €183 to €546
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €477,190 | €456,449 | -€20,741 | -4.3% |
| Current assets | 29/58 | €477,190 | €456,449 | -€20,741 | -4.3% |
| Amounts receivable within one year | 40/41 | €13 | €5 | -€8 | -64.1% |
| Other amounts receivable | 41 | €13 | €5 | -€8 | -64.1% |
| Cash at bank and in hand | 54/58 | €134,044 | €172,407 | +€38,363 | +28.6% |
| Deferred charges and accrued income | 490/1 | €343,133 | €284,037 | -€59,096 | -17.2% |
| Total equity and liabilities | 10/49 | €477,190 | €456,449 | -€20,741 | -4.3% |
| Equity | 10/15 | €9,570 | €17,918 | +€8,348 | +87.2% |
| Contributions | 10/11 | €21,079 | €21,079 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€11,509 | -€3,161 | +€8,348 | +72.5% |
| Amounts payable | 17/49 | €467,620 | €438,531 | -€29,089 | -6.2% |
| Amounts payable within one year | 42/48 | - | €568 | +€568 | |
| Trade debts | 44 | - | €61 | +€61 | |
| Suppliers | 440/4 | - | €61 | +€61 | |
| Other amounts payable | 47/48 | - | €507 | +€507 | |
| Accrued charges and deferred income | 492/3 | €467,620 | €437,962 | -€29,658 | -6.3% |
| Other operating charges | 640/8 | €469 | €442 | -€26 | -5.6% |
| Gross operating margin | 9900 | -€22,256 | €9,320 | +€31,576 | |
| Operating profit (loss) | 9901 | -€22,725 | €8,878 | +€31,602 | |
| Financial income | 75/76B | €44 | €16 | -€28 | -64.1% |
| Recurring financial income | 75 | €44 | €16 | -€28 | -64.1% |
| Financial charges | 65/66B | €183 | €546 | +€362 | +198% |
| Recurring financial charges | 65 | €183 | €546 | +€362 | +198% |
| Profit (loss) for the period before taxes | 9903 | -€22,864 | €8,348 | +€31,212 | |
| Income taxes | 67/77 | €0 | €0 | = | |
| Profit (loss) for the period | 9904 | -€22,864 | €8,348 | +€31,212 | |
| Profit (loss) for the period to be appropriated | 9905 | -€22,864 | €8,348 | +€31,212 |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 30 June 2024 and 30 June 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 3 November 2026 via checked.be.